CA2401448A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Download PDF

Info

Publication number
CA2401448A1
CA2401448A1 CA002401448A CA2401448A CA2401448A1 CA 2401448 A1 CA2401448 A1 CA 2401448A1 CA 002401448 A CA002401448 A CA 002401448A CA 2401448 A CA2401448 A CA 2401448A CA 2401448 A1 CA2401448 A1 CA 2401448A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
shows
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401448A
Other languages
English (en)
Inventor
Kevin P. Baker
Jian Chen
Luc Desnoyers
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
James Pan
Victoria Smith
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority to CA002533903A priority Critical patent/CA2533903A1/fr
Priority to CA002534030A priority patent/CA2534030A1/fr
Priority to CA002534186A priority patent/CA2534186A1/fr
Priority to CA002539214A priority patent/CA2539214A1/fr
Priority to CA002533831A priority patent/CA2533831A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002534391A priority patent/CA2534391A1/fr
Priority to CA002531917A priority patent/CA2531917A1/fr
Priority to CA002534018A priority patent/CA2534018A1/fr
Priority to CA002533991A priority patent/CA2533991A1/fr
Publication of CA2401448A1 publication Critical patent/CA2401448A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux polypeptides et des molécules d'acides nucléiques codant ces polypeptides ainsi que des vecteurs et des cellules hôtes comprenant ces séquences d'acides nucléiques, des molécules de polypeptides chimères comprenant les polypeptides de l'invention fusionnés à des séquences de polypeptides hétérologues, des anticorps se liant aux polypeptides de la présente invention et des procédés pour produire les polypeptides de la présente invention.
CA002401448A 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides Abandoned CA2401448A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002533831A CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534018A CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides

Applications Claiming Priority (80)

Application Number Priority Date Filing Date Title
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05601 2000-03-01
USPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US18696800P 2000-03-06 2000-03-06
US60/186,968 2000-03-06
US18932000P 2000-03-14 2000-03-14
US18932800P 2000-03-14 2000-03-14
US60/189,320 2000-03-14
US60/189,328 2000-03-14
USPCT/US00/06884 2000-03-15
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
US19082800P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US19131400P 2000-03-21 2000-03-21
US19104800P 2000-03-21 2000-03-21
US60/191,007 2000-03-21
US60/190,828 2000-03-21
US60/191,314 2000-03-21
US60/191,048 2000-03-21
US19265500P 2000-03-28 2000-03-28
US60/192,655 2000-03-28
US19303200P 2000-03-29 2000-03-29
US19305300P 2000-03-29 2000-03-29
US60/193,053 2000-03-29
US60/193,032 2000-03-29
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
USPCT/US00/08439 2000-03-30
US19464700P 2000-04-04 2000-04-04
US19444900P 2000-04-04 2000-04-04
US60/194,449 2000-04-04
US60/194,647 2000-04-04
US19597500P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US19600000P 2000-04-11 2000-04-11
US19669000P 2000-04-11 2000-04-11
US19682000P 2000-04-11 2000-04-11
US60/195,975 2000-04-11
US60/196,187 2000-04-11
US60/196,690 2000-04-11
US60/196,000 2000-04-11
US60/196,820 2000-04-11
US19858500P 2000-04-18 2000-04-18
US19812100P 2000-04-18 2000-04-18
US60/198,585 2000-04-18
US60/198,121 2000-04-18
US19955000P 2000-04-25 2000-04-25
US19939700P 2000-04-25 2000-04-25
US19965400P 2000-04-25 2000-04-25
US60/199,550 2000-04-25
US60/199,397 2000-04-25
US60/199,654 2000-04-25
US20151600P 2000-05-03 2000-05-03
US60/201,516 2000-05-03
USPCT/US00/13705 2000-05-17
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14042 2000-05-22
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
USPCT/US00/14941 2000-05-30
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
USPCT/US00/15264 2000-06-02
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
USPCT/US00/20710 2000-07-28
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US64484800A 2000-08-22 2000-08-22
US09/644,848 2000-08-22
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/23328 2000-08-24
US60/000,000 2000-09-15
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
USPCT/US00/30952 2000-11-08
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/32678 2000-12-01
USPCT/US00/34956 2000-12-20
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Related Child Applications (9)

Application Number Title Priority Date Filing Date
CA002534018A Division CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533903A Division CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Division CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Division CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A Division CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002534391A Division CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Division CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Division CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Division CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Publications (1)

Publication Number Publication Date
CA2401448A1 true CA2401448A1 (fr) 2001-09-20

Family

ID=40231083

Family Applications (10)

Application Number Title Priority Date Filing Date
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002401448A Abandoned CA2401448A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA002534018A Abandoned CA2534018A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002539214A Abandoned CA2539214A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533831A Abandoned CA2533831A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Applications After (6)

Application Number Title Priority Date Filing Date
CA002534391A Abandoned CA2534391A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002531917A Abandoned CA2531917A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002533991A Abandoned CA2533991A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
CA002533903A Abandoned CA2533903A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534030A Abandoned CA2534030A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
CA002534186A Abandoned CA2534186A1 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2534018A1 (fr)
WO (1) WO2001068848A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018412A1 (fr) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 17 protéines humaines sécrétées
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP1005544A4 (fr) 1997-08-19 2004-07-14 Human Genome Sciences Inc 70 proteines secretees humaines
WO1999012963A2 (fr) 1997-09-12 1999-03-18 Biogen, Inc. Recepteurs 'trail' riches en cysteine
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
WO1999014240A1 (fr) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Proteine de type recepteur d'interleukine 17
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
NZ515382A (en) * 1999-05-13 2004-03-26 Medical Res Council OX2 receptor homologs
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1623991A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
JP2003514524A (ja) 1999-11-18 2003-04-22 コルバス・インターナショナル・インコーポレイテッド エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US20020155499A1 (en) * 2000-09-25 2002-10-24 Leiby Kevin R. 32624, a novel human UDP-glucuronosyl and glycosyl transferase family member and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001083781A2 (fr) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412377A1 (fr) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company Acides nucleiques et polypeptides apparentes a b7 utiles pour effectuer une immunomodulation
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001268440A1 (en) * 2000-06-15 2002-01-08 Millennium Pharmaceuticals, Inc. 53320, a human acyltransferase and uses therefor
AU7005801A (en) * 2000-06-22 2002-01-02 Biogen Inc Gp354 nucleic acids and polypeptides
AU2001273194A1 (en) * 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
CA2416732C (fr) 2000-08-02 2016-02-09 Brad St. Croix Profils d'expression de cellules endotheliales
EP1313858A2 (fr) * 2000-09-01 2003-05-28 Millennium Pharmaceuticals, Inc. Kinases humaines 16658, 14223, et 16002, et utilisations
WO2002040654A2 (fr) 2000-11-14 2002-05-23 Bristol-Myers Squibb Company Polynucleotide codant pour une nouvelle serpine humaine (lsi-01) secretee a partir des cellules lymphoides
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
JPWO2002064769A1 (ja) * 2001-02-15 2004-06-17 塩野義製薬株式会社 新規疾患マーカー
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
JP2004533222A (ja) * 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
WO2002072786A2 (fr) 2001-03-13 2002-09-19 Corvas International, Inc. Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
CA2442089A1 (fr) 2001-03-27 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2443909A1 (fr) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Polynucleotides codant deux nouveaux recepteurs couples aux proteines g, hgprbmy28 et hgprbmy29, et leurs variants d'epissage
JP2005506832A (ja) 2001-05-14 2005-03-10 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー トランスメンブランセリンプロテアーゼ１０をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003000021A2 (fr) * 2001-06-22 2003-01-03 Biogen, Inc. Acides nucleiques et polypeptides pancam
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
IL159872A0 (en) * 2001-07-26 2004-06-20 Genset Sa Gmg-2 polypeptides and their use
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
EP1428881A4 (fr) 2001-08-23 2006-05-17 Japan Science & Tech Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
EP1487877B1 (fr) * 2001-09-18 2010-10-27 Genentech, Inc. Compositions et procedes pour le diagnostic de tumeurs
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
WO2003039462A2 (fr) * 2001-11-02 2003-05-15 Tanox, Inc. Antigene specifique du lymphome des lymphocytes b destine a etre utilise dans le diagnostic et le traitement des malignites des lymphocytes b
AU2002359815A1 (en) 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2005523311A (ja) * 2002-04-17 2005-08-04 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
DE60319529T2 (de) * 2002-05-31 2008-10-23 Seikagaku Corp. Chondroitinsynthetase und das enzym codierende nukleinsäure
WO2003102182A1 (fr) * 2002-05-31 2003-12-11 Hidetoshi Inoko Gene slurp-2 associe a une maladie de peau inflammatoire et utilisation de ce gene
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
AU2003267097B2 (en) * 2002-09-11 2009-09-17 Genentech, Inc. Novel composition and methods for the treatment of psoriasis
DE10242016A1 (de) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2511522A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
CA2511556A1 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
JP2006518193A (ja) * 2003-01-16 2006-08-10 ユニバーシティ オブ バージニア パテント ファウンデーション 精子特異的リゾチーム様タンパク質
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
WO2005019270A2 (fr) 2003-08-14 2005-03-03 Dyax Corp. Ligands de l'endotheliase-2
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
CA2551546A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7410772B2 (en) 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
CA2576193A1 (fr) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Influence du taj sur les fonctions neuronales
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
EP2082645A1 (fr) * 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
WO2008019351A2 (fr) 2006-08-04 2008-02-14 Isis Pharmaceuticals, Inc. Compositions et leurs utilisations dirigées sur la diacylglycérol acyltransférase 1
ES2625259T3 (es) 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
CA2759848C (fr) 2009-05-05 2018-12-04 Novimmune S.A. Anticorps anti-il-17f et leurs methodes d'utilisation
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CA2888803A1 (fr) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procedes d'utilisation de tels peptides et compositions
WO2014075788A1 (fr) 2012-11-13 2014-05-22 Biontech Ag Agents de traitement de maladies cancéreuses exprimant claudine
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
CA2991894A1 (fr) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulateurs de diacylglycerol acyltransferase 2 (dgat2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
CA2383592A1 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; orfx
ATE478145T1 (de) * 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
WO2001040269A2 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
CA2399776A1 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides
KR20030029847A (ko) * 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
CA2533991A1 (fr) 2001-09-20
CA2534391A1 (fr) 2001-09-20
WO2001068848A3 (fr) 2002-08-29
JP2006081548A (ja) 2006-03-30
CA2534018A1 (fr) 2001-09-20
CA2533831A1 (fr) 2001-09-20
CA2539214A1 (fr) 2001-09-20
WO2001068848A2 (fr) 2001-09-20
CA2534030A1 (fr) 2001-09-20
CA2533903A1 (fr) 2001-09-20
AU2001268028A1 (en) 2001-09-24
CA2534186A1 (fr) 2001-09-20
AU6802801A (en) 2001-09-24
CA2531917A1 (fr) 2001-09-20
JP2004508805A (ja) 2004-03-25
JP2008301822A (ja) 2008-12-18
EP1259614A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
US7189838B2 (en) PRO9834 nucleic acids
US20030170801A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2401448A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US20040023321A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104548A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104547A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030104551A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead